Development of novel targeted agents in the treatment of metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 10, Issue 4, 2011, Pages 266-278

  Berge, Eamon ^a   Thompson, Chris ^a   Messersmith, Wells ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

EGFR; MAPK pathway; PI3K AKT pathway; Targeted therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; AFATINIB; CETUXIMAB; CIXUTUMUMAB; DABRAFENIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FIGITUMUMAB; GANITUMAB; IRINOTECAN; LINSITINIB; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; NECITUMUMAB; NIMOTUZUMAB; PANITUMUMAB; PEGVISOMANT; PERIFOSINE; PICTRELISIB; RAF PROTEIN; RAS PROTEIN; SELUMETINIB; UNINDEXED DRUG; VEMURAFENIB; XL 147; XL 228; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE;

APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER SCREENING; CANCER STEM CELL; COLORECTAL CANCER; DNA REPAIR; IMMUNOTHERAPY; METASTASIS; MONOTHERAPY; REVIEW;

EID: 84855932581     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.06.011     Document Type: Review

References (131)

1. Cancer Facts and Figures 2010 http://www.cancer.org Accessed January 10, 2011
2. G. Carpenter, and S. Cohen Epidermal growth factor J Biol Chem 265 1990 7709 7712 (Pubitemid 20158927)
3. F. Ciardiello, and G. Tortora EGFR antagonists in cancer treatment N Engl J Med 358 2008 1160 1174
4. B. Markman, C. Gomez-Roca, and A. Cervantes-Ruiperez Phase I PK/PD study of RO5083945 (GA201), the first glycoengineered anti-EGFR monoclonal antibody (mAb) with optimized antibody dependent cellular cytotoxicity (ADCC) J Clin Oncol 28 suppl 2010 abstract 2522 http://www.asco.org Accessed June 30, 2011
5. B. Kuenen, P.O. Witteveen, and R. Ruijter A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies Clin Cancer Res 16 2010 1915 1923
6. B. You, A. Brade, and J.M. Magalhaes A dose-escalation phase I trial of nimotuzumab an antibody against the epidermal growth factor receptor in patients with advanced solid malignancies Invest New Drugs 2010 May 8 [Epub ahead of print]
7. M.W. Pedersen, H.J. Jacobsen, and K. Koefoed Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy Cancer Res 70 2010 588 597
8. T.A. Yap, L. Vidal, and J. Adam Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors J Clin Oncol 28 2010 3965 3972
9. S. Schubbert, K. Shannon, and G. Bollag Hyperactive Ras in developmental disorders and cancer Nat Rev Cancer 7 2007 295 308 (Pubitemid 46480970)
10. A. Bardelli, and S. Siena Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer J Clin Oncol 28 2010 1254 1261
11. C.S. Karapetis, S. Khambata-Ford, and D.J. Jonker K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
12. J. Zujewski, I.D. Horak, and C.J. Bol Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer J Clin Oncol 18 2000 927 941 (Pubitemid 30106625)
13. J.E. Karp, J.E. Lancet, and S.H. Kaufmann Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial Blood 97 2001 3361 3369
14. S. Rao, D. Cunningham, and A. de Gramont Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer J Clin Oncol 22 2004 3950 3957 (Pubitemid 41079877)
15. M.J. Garnett, and R. Marais Guilty as charged: B-RAF is a human oncogene Cancer Cell 6 2004 313 319 (Pubitemid 39361432)
16. V. Deschoolmeester, M. Baay, and P. Specenier A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy Oncologist 15 2010 699 731
17. H. Davies, G.R. Bignell, and C. Cox Mutations of the BRAF gene in human cancer Nature 417 2002 949 954 (Pubitemid 34716871)
18. C.P. Vaughn, A.R. Wilson, and W.S. Samowitz Quantitative evaluation of CpG island methylation in hyperplastic polyps Mod Pathol 23 2010 151 156
19. F. Di Nicolantonio, M. Martini, and F. Molinari Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 2008 5705 5712
20. P. Laurent-Puig, A. Cayre, and G. Manceau Analysis of PTEN BRAF and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer J Clin Oncol 27 2009 5924 5930
21. E. Van Cutsem, I. Lang, and G. Folprecht Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome J Clin Oncol 28 suppl 2010 abstract 3570 http://www.asco.org Accessed June 30, 2011
22. K. Flaherty, I. Puzanov, and J. Sosman Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer J Clin Oncol 27 suppl 2009 abstract 9000 http://www.asco.org Accessed June 30, 2011
23. G.K. Schwartz, S. Robertson, and A. Shen A phase I study of XL281 a selective oral RAF kinase inhibitor in patients (pts) with advanced solid tumors J Clin Oncol 27 suppl 2009 abstract 3513 http://www.asco.org Accessed June 30, 2011
24. R. Kefford, H. Arkenau, and M.P. Brown Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase in patients with metastatic melanoma and other solid tumors J Clin Oncol 28 suppl 2010 abstract 8503 http://www.asco.org Accessed June 30, 2011
25. A. Grothey, J.M. Lafky, and B.W. Morlan Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): results of the phase II North Central Cancer Treatment Group study N054C J Clin Oncol 28 suppl 2010 abstract 3549 http://www.asco.org Accessed June 30, 2011
26. M. Ychou, E. Francois, and S. Thezenas Sorafenib (S) in combination with irinotecan (I) as a treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS mutation (mt) as second line or later: interim analysis results of multicenter phase II part trial (NEXIRI) J Clin Oncol 28 suppl 2010 abstract e14022 http://www.asco.org Accessed June 30, 2011
27. J.S. Sebolt-Leopold MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors Curr Pharm Des 10 2004 1907 1914 (Pubitemid 38647576)
28. P. Liu, H. Cheng, and T.M. Roberts Targeting the phosphoinositide 3-kinase pathway in cancer Nat Rev Drug Discov 8 2009 627 644
29. Y. Keshet, R. R Seger The MAP kinase signaling cascades a system of hundreds of components regulates a diverse array of physiological functions Methods Mol Biol 661 2010 3 38
30. J. Avruch MAP kinase pathways the first twenty years Biochim Biophys Acta 1773 2007 1150 1160
31. J.S. Sebolt-Leopold, D.T. Dudley, and R. Herrera Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo Nat Med 5 1999 810 816 (Pubitemid 29318616)
32. P.M. Lorusso, A.A. Adjei, and M. Varterasian Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies J Clin Oncol 23 2005 5281 5293 (Pubitemid 46206982)
33. J. Rinehart, A.A. Adjei, and P.M. Lorusso Multicenter phase II study of the oral MEK inhibitor CI-1040 in patients with advanced non-small-cell lung breast colon and pancreatic cancer J Clin Oncol 22 2004 4456 4462 (Pubitemid 41185111)
34. P. Lorusso, S. Krishnamurthi, and J.R. Rinehart A phase 1-2 clinical study of a second generation oral MEK inhibitor PD 0325901 in patients with advanced cancer J Clin Oncol 23 suppl 2005 abstract 3011 http://www.asco.org Accessed June 30, 2011
35. A.A. Adjei, R.M. Cohen, and W. Franklin Phase I pharmacokinetic and pharmacodynamic study of the oral small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers J Clin Oncol 26 2008 2139 2146
36. J. Bennouna, I. Lang, and M. Valladares-Ayerbes A phase II open-label randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens Invest New Drugs 2010 Feb 2 [Epub ahead of print]
37. J.R. Infante, L.A. Fecher, and S. Nallapareddy Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212 J Clin Oncol 28 suppl 2010 abstract 2503 http://www.asco.org Accessed June 30, 2011
38. C. Mala, N.G. Neville, and E. Haindl A phase I first-in-human single ascending dose study of the MEK inhibitor WX-554 given to healthy male subjects J Clin Oncol 28 suppl 2010 abstract e13666 http://www.asco.org Accessed June 30, 2011
39. J. Delord, A. Houede, and N. Awada First-in-human phase I safety pharmacokinetic (PK) and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors J Clin Oncol 28 suppl 2010 abstract 2504 http://www.asco.org Accessed June 30, 2011
40. L. Paz-Ares, C. Blanco-Aparicio, and R. Garcia-Carbonero Inhibiting PI3K as a therapeutic strategy against cancer Clin Transl Oncol 11 2009 572 579
41. A.Blons Lievre, and P. Laurent-Puig Oncogenic mutations as predictive factors in colorectal cancer Oncogene 29 2010 3033 3043
42. J. Baselga, M.J. De Jonge, and J. Rodon A first-in-human phase I study of BKM120 an oral pan-class I PI3K inhibitor in patients (pts) with advanced solid tumors J Clin Oncol 28 suppl 2010 abstract 3003 http://www.asco.org Accessed June 30, 2011
43. H. Burris, J. Rodon, and S. Sharma First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors J Clin Oncol 28 suppl 2010 abstract 3005 http://www.asco.org Accessed June 30, 2011
44. P. LoRusso, B. Markman, and J. Tabernero A phase I dose-escalation study of the safety pharmacokinetics (PK) and pharmacodynamics of XL765 a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors J Clin Oncol 27 suppl 2009 abstract 3502 http://www.asco.org Accessed June 30, 2011
45. K.D. Courtney, R.B. Corcoran, and J.A. Engelman The PI3K pathway as drug target in human cancer J Clin Oncol 28 2010 1075 1083
46. G. Shapiro, E. Kwak, and J. Baselga Phase I dose-escalation study of XL147 a PI3K inhibitor administered orally to patients with solid tumors J Clin Oncol 27 suppl 2009 abstract 3500 http://www.asco.org Accessed June 30, 2011
47. A.J. Wagner, D.H. Von Hoff, and P.M. LoRusso A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors J Clin Oncol 27 suppl 2009 abstract 3501 http://www.asco.org Accessed June 30, 2011
48. R.D. Baird, R.S. Kristeleit, and D. Sarker A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941 J Clin Oncol 27 suppl 2009 abstract 3538 http://www.asco.org Accessed June 30, 2011
49. D.A. Richards, S.J. Nemunaitis, and J.J. Vukelja Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC) J Clin Oncol 28 suppl 2010 abstract 3531 http://www.asco.org Accessed June 30, 2011
50. C. Unger, W. Berdel, and A.R. Hanauske First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours Eur J Cancer 46 2010 920 925
51. M.N. Pollak, E.S. Schernhammer, and S.E. Hankinson Insulin-like growth factors and neoplasia Nat Rev Cancer 4 2004 505 518 (Pubitemid 38868620)
52. R.G. Maki Small is beautiful: insulin-like growth factors and their role in growth development and cancer J Clin Oncol 28 2010 4985 4995
53. E. Giovannucci, M. Pollak, and E.A. Platz Insulin-like growth factor I (IGF-I) IGF-binding protein-3 and the risk of colorectal adenoma and cancer in the Nurses' Health Study Growth Horm IGF Res 10 suppl A 2000 S30 S31
54. K.J. Hunt, P. Toniolo, and A. Akhmedkhanov Insulin-like growth factor II and colorectal cancer risk in women Cancer Epidemiol Biomarkers Prev 11 2002 901 905 (Pubitemid 35014895)
55. R. Palmqvist, G. Hallmans, and S. Rinaldi Plasma insulin-like growth factor 1 insulin-like growth factor binding protein 3 and risk of colorectal cancer: a prospective study in northern Sweden Gut 50 2002 642 646 (Pubitemid 34407490)
56. C. Lemne, and K. Brismar Insulin-like growth factor binding protein-1 as a marker of the metabolic syndromea study in borderline hypertension Blood Press 7 1998 89 95 (Pubitemid 28277473)
57. R. Pais, H. Silaghi, and A.C. Silaghi Metabolic syndrome and risk of subsequent colorectal cancer World J Gastroenterol 15 2009 5141 5148
58. M.S. Sandhu, D.B. Dunger, and E.L. Giovannucci Insulin insulin-like growth factor-I (IGF-I) IGF binding proteins their biologic interactions and colorectal cancer J Natl Cancer Inst 94 2002 972 980 (Pubitemid 34814726)
59. A. Hakam, T.J. Yeatman, and L. Lu Expression of insulin-like growth factor-1 receptor in human colorectal cancer Hum Pathol 30 1999 1128 1133 (Pubitemid 29480878)
60. A. Hopkins, P.J. Crowe, and J.L. Yang Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved J Cancer Res Clin Oncol 136 2010 639 650
61. P. Haluska, H.M. Shaw, and G.N. Batzel Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751871 in patients with refractory solid tumors Clin Cancer Res 13 2007 5834 5840 (Pubitemid 47583908)
62. P. Haluska, F. Worden, and D. Olmos Safety tolerability and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma Cancer Chemother Pharmacol 65 2010 765 773
63. A.W. Tolcher, J. Sarantopoulos, and A. Patnaik Phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1 J Clin Oncol 27 2009 5800 5807
64. F. Atzori, J. Tabernero, and A. Cervantes A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646 an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors abstract 3519 J Clin Oncol 26 suppl 2008 http://www.asco.org Accessed June 30, 2011
65. C.S. Higano, E.Y. Yu, and S.H. Whiting A phase I first in man study of weekly IMC-A12 a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody in patients with advanced solid tumors abstract 3505 J Clin Oncol 25 suppl 2007 http://www.asco.org Accessed June 30, 2011
66. D. Olmos, S. Postel-Vinay, and L.R. Molife Safety pharmacokinetics and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study Lancet Oncol 11 2010 129 135
67. L.R. Molife, P.C. Fong, and L. Paccagnella The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation open-label study Br J Cancer 103 2010 332 339
68. J. Jassem, C.J. Langer, and D.D. Karp Randomized open label phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) abstract 7500 J Clin Oncol 28 suppl 2010 http://www.asco.org Accessed June 30, 2011
69. D.L. Reidy, E. Vakiani, and M.G. Fakih randomized phase ii study of the insulin-like growth factor-1 receptor inhibitor IMC-A12 with or without cetuximab in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer J Clin Oncol 28 2010 4240 4246
70. T. Evans, C.R. Lindsay, and E. Chan Phase I dose-escalation study of continuous oral dosing of OSI-906 a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors J Clin Oncol 28 suppl 2010 abstract 2531 http://www.asco.org Accessed June 30, 2011
71. V.M. Macaulay, M.R. Middleton, and S.G. Eckhardt Phase I study of OSI-906 dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors abstract 3016 J Clin Oncol 28 suppl 2010 http://www.asco.org Accessed June 30, 2011
72. T. Trarbach, M. Moehler, and V. Heinemann Phase II trial of mapatumumab a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1) in patients with refractory colorectal cancer Br J Cancer 102 2010 506 512
73. S.R. Wiley, K. Schooley, and P.J. Smolak Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 1995 673 682 (Pubitemid 26091143)
74. C.M. Van Geelen, E.G. de Vries, and S. de Jong Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy Drug Resist Updat 7 2004 345 358 (Pubitemid 40341956)
75. J. Wen, N. Ramadevi, and D. Nguyen Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells Blood 96 2000 3900 3906
76. J. Wiezorek, P. Holland, and J. Graves Death receptor agonists as a targeted therapy for cancer Clin Cancer Res 16 2010 1701 1708
77. L. Yee, H.A. Burris, and M. Kozloff Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): Preliminary results abstract 4129 J Clin Oncol 27 suppl 2009 http://www.asco.org Accessed June 30, 2011
78. T. Naka, K. Sugamura, and B.L. Hylander Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice Cancer Res 62 2002 5800 5806 (Pubitemid 35204738)
79. A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated Locally Advanced Recurrent or Metastatic Colorectal Cancer http://clinicaltrialsgov/ct2/show/ NCT00873756 Accessed January 12, 2011
80. A Study of dulanermin administered in combination with Camptosar®/Erbitux® chemotherapy or FOLFIRI (with or without bevacizumab) in subjects with previously treated metastatic colorectal cancer http://clinicaltrials.gov/ct2/show/NCT00671372 January 1 2011 Accessed June 30, 2011
81. A study of PRO95780 administered in combination with the FOLFOX regimen and bevacizumab in patients with previously untreated locally advanced recurrent and metastatic colorectal cancer (APM4566g) http://clinicaltrials.gov/ct2/show/ NCT00851136 Accessed January 6 2011
82. L. Saltz, J. Infante, and L. Schwartzberg Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC) J Clin Oncol 27 2009 abstract 4079
83. J.H. Hoeijmakers DNA damage aging and cancer N Engl J Med 361 2009 1475 1485
84. S.K. Sandhu, T.A. Yap, and J.S. de Bono Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective Eur J Cancer 46 2010 9 20
85. A. Mangerich, and A. Burkle How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation Int J Cancer 128 2011 251 265
86. J.C. Ame, V. Rolli, and V. Schreiber PARP-2 A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase J Biol Chem 274 1999 17860 17868
87. L.G. Ball, and W. Xiao Molecular basis of ataxia telangiectasia and related diseases Acta Pharmacol Sin 26 2005 897 907 (Pubitemid 41153209)
88. W.G. Kaelin Jr The concept of synthetic lethality in the context of anticancer therapy Nat Rev Cancer 5 2005 689 698 (Pubitemid 41486362)
89. E. Vilar, and S.B. Gruber Microsatellite instability in colorectal cancer-the stable evidence Nat Rev Clin Oncol 7 2010 153 162
90. E. Vilar Sanchez, A. Chow, and L. Raskin Preclinical testing of the PARP inhibitor ABT-888 in microsatellite instable colorectal cancer J Clin Oncol 27 suppl 2009 abstract 11028 http://www.asco.org Accessed June 30, 2011
91. L. Leichman, S. Cohen, and H. Hochster A phase II trial to assess the single-agent efficacy and safety of the PARP inhibitor olaparib (O) in previously treated patients (pts) with metastatic measurable colorectal cancer (mCRC) stratified by microsatellite status (MSs) Paper presented at 2010 Molecular Markers Symposium, Orlando FL. Abstract 118 http://www.asco.org Accessed June 30, 2011
92. P.W. Ingham, and A.P. McMahon Hedgehog signaling in animal development: paradigms and principles Genes Dev 15 2001 3059 3087 (Pubitemid 33115673)
93. P.A. Beachy, S.S. Karhadkar, and D.M. Berman Tissue repair and stem cell renewal in carcinogenesis Nature 432 2004 324 331 (Pubitemid 39551660)
94. V. Medina, M.B. Calvo, and S. Diaz-Prado Hedgehog signalling as a target in cancer stem cells Clin Transl Oncol 11 2009 199 207
95. A.A. Merchant, and W. Matsui Targeting Hedgehoga cancer stem cell pathway Clin Cancer Res 16 2010 3130 3140
96. R.L. Johnson, A.L. Rothman, and J. Xie Human homolog of patched a candidate gene for the basal cell nevus syndrome Science 272 1996 1668 1671 (Pubitemid 26200029)
97. Y.H. Bian, S.H. Huang, and L. Yang Sonic hedgehog-Gli1 pathway in colorectal adenocarcinomas World J Gastroenterol 13 2007 1659 1665 (Pubitemid 46711335)
98. J.W. Theunissen, and F.J. de Sauvage Paracrine Hedgehog signaling in cancer Cancer Res 69 2009 6007 6010
99. D.M. Berman, S.S. Karhadkar, and A. Maitra Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours Nature 425 2003 846 851 (Pubitemid 37351469)
100. C.M. Rudin, C.L. Hann, and J. Laterra Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449 N Engl J Med 361 2009 1173 1178
101. D.D. Von Hoff, P.M. LoRusso, and C.M. Rudin Inhibition of the hedgehog pathway in advanced basal-cell carcinoma N Engl J Med 361 2009 1164 1172
102. J.C. Bendell, L.L. Hart, and I. Firdaus Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) abstract 3530 J Clin Oncol 28 suppl 2010 http://www.asco.org Accessed June 30, 2011
103. Curis Announces Genentech's Phase II Clinical Trial Results of GDC-0449 in Combination with Avastin(R) and Chemotherapy in First-Line Metastatic Colorectal Cancer http://www.drugs.com/clinical-trials/curis-announces- genentech-s-phase-ii-clinical-trial-results-gdc-0449-combination-avastin-9631. html June 16, 2010 Accessed June 30, 2011
104. J. Rodon Ahnert, J. Baselga, and H.A. Tawbi A phase I dose-escalation study of LDE225 a smoothened (Smo) antagonist in patients with advanced solid tumors abstract 2500 J Clin Oncol 28 suppl 2010 http://www.asco.org Accessed June 30, 2011
105. L.L. Siu, K. Papadopoulos, and S.R. Alberts A first-in-human phase I study of an oral hedgehog (HH) pathway antagonist BMS-833923 (XL139) in subjects with advanced or metastatic solid tumors abstract 2501 J Clin Oncol 28 suppl 2010 http://www.asco.org Accessed June 30, 2011
106. K.A. Wharton, K.M. Johansen, and Xu T Nucleotide sequence from the neurogenic locus notch implies a gene product that shares homology with proteins containing EGF-like repeats Cell 43 Pt 2 1985 567 581
107. F. Radtke, and K. Raj The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 3 2003 756 767 (Pubitemid 37328814)
108. L. Yin, O.C. Velazquez, and Z.J. Liu Notch signaling: emerging molecular targets for cancer therapy Biochem Pharmacol 80 2010 690 701
109. A.P. Weng, A.A. Ferrando, and W. Lee Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia Science 306 2004 269 271 (Pubitemid 39336870)
110. A.M. Jubb, H. Turley, and H.C. Moeller Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer Br J Cancer 101 2009 1749 1757
111. R.D. Meng, C.C. Shelton, and Y.M. Li gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity Cancer Res 69 2009 573 582
112. M. Reedijk, S. Odorcic, and H. Zhang Activation of Notch signaling in human colon adenocarcinoma Int J Oncol 33 2008 1223 1229
113. S.S. Sikandar, K.T. Pate, and S. Anderson NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer Cancer Res 70 2010 1469 1478
114. L. Ricci-Vitiani, D.G. Lombardi, and E. Pilozzi Identification and expansion of human colon-cancer-initiating cells Nature 445 2007 111 115 (Pubitemid 46067311)
115. A.W. Tolcher, S.M. Mikulski, and W.A. Messersmith A phase I study of RO4929097 a novel gamma secretase inhibitor in patients with advanced solid tumors abstract 2502 J Clin Oncol 28 suppl 2010 http://www.asco.org Accessed June 30, 2011
116. F. Takahashi-Yanaga, and M. Kahn Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 16 2010 3153 3162
117. W.F. Bodmer, C.J. Bailey, and J. Bodmer Localization of the gene for familial adenomatous polyposis on chromosome 5 Nature 328 1987 614 616 (Pubitemid 17103960)
118. E. Solomon, R. Voss, and V. Hall Chromosome 5 allele loss in human colorectal carcinomas Nature 328 1987 616 619 (Pubitemid 17103961)
119. P.J. Morin, A.B. Sparks, and V. Korinek Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC Science 275 1997 1787 1790 (Pubitemid 27136715)
120. J. Espada, M.B. Calvo, and S. Diaz-Prado Wnt signalling and cancer stem cells Clin Transl Oncol 11 2009 411 427
121. P. Polakis Wnt signaling and cancer Genes Dev 14 2000 1837 1851 (Pubitemid 30639518)
122. J.P. Rey, and D.L. Ellies Wnt modulators in the biotech pipeline Dev Dyn 239 2010 102 114
123. D. Padhi, G. Jang, and B. Stouch Single-dose placebo-controlled randomized study of AMG 785, a sclerostin monoclonal antibody J Bone Miner Res 26 2011 19 26
124. M. Martinez, C. Hope, and K. Planutis Dietary grape-derived resveratrol for colon cancer prevention abstract 3622 J Clin Oncol 28 suppl 2010 http://www.asco.org Accessed June 30, 2011
125. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
126. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
127. S. Mosolits, G. Ullenhag, and H. Mellstedt Therapeutic vaccination in patients with gastrointestinal malignancies A review of immunological and clinical results Ann Oncol 16 2005 847 862 (Pubitemid 40903909)
128. J. Galon, A. Costes, and F. Sanchez-Cabo Type density and location of immune cells within human colorectal tumors predict clinical outcome Science 313 2006 1960 1964 (Pubitemid 44498003)
129. L. Novellino, C. Castelli, and G. Parmiani A listing of human tumor antigens recognized by T cells: March 2004 update Cancer Immunol Immunother 54 2005 187 207 (Pubitemid 40174238)
130. D. Nagorsen, and E. Thiel Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer Clin Cancer Res 12 2006 3064 3069 (Pubitemid 43837352)
131. J.D. Wolchok, A. Hoos, and S. O'Day Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 2009 7412 7420